Updated on Oct 10, 2026 Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company focused on Class III and Class C/D devices, primarily in the fields of vascular and structural heart intervention. The company was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer—Infinnium. The product portfolio spans three key categories: Vascular Intervention (VI): Includes coronary stents and balloons for minimally invasive blood vessel treatments. Structural Heart (SH): Covers advanced technologies such as Transcatheter Aortic Valve Implantation (TAVI) and Occluders. Other Products: Includes renal stents, peripheral Drug-Coated Balloons (DCBs), and selected trading products. Sahajanand operates two R&D centers—one in India and one in Thailand—supported by a team of 102 professionals, including biomedical engineers and clinical research specialists.
| Category | Bid by (IST) |
|---|---|
| QIB | 4:00 PM |
| NII / HNI | 4:00 PM |
| Retail | 5:00 PM |
| UPI mandate approval | 5:00 PM |
Exchange cut-offs on the closing day. Your broker may set an earlier internal deadline - apply well before, and approve the UPI mandate before 5:00 PM. Times can change; verify with your broker.
Aggregated by CoinWhisperer for convenience. Figures (GMP, subscription, price band) can change and may be delayed - always verify on the official source and with your broker before applying. Do your own research.